Monitor the ESMO presentation and investor webcast on October 24 for actual efficacy/safety data from the dose optimization cohort — this will determine whether the Phase 3 registrational trial design is derisked. No data is provided in this press release, so the stock impact depends entirely on the topline results disclosed at the conference.
Price Chart
Executive Summary
Parabilis Medicines announced an upcoming oral presentation at ESMO 2026 of updated Phase 1/2 data for zolucatetide in desmoid tumors, with a June 22, 2026 data cutoff including dose optimization results to inform Phase 3 registrational trial design. The drug has FDA Fast Track and Orphan Drug designations for desmoid tumors, and the company will host an investor webcast on October 24, 2026. This is a routine clinical data update milestone for a clinical-stage biotech — no efficacy or safety results are disclosed in this press release, so the event is neutral pending actual data readout.
Key Facts
- Oral presentation at ESMO Congress 2026 (October 23–27, Madrid) reporting updated Phase 1/2 data for zolucatetide in desmoid tumors with a June 22, 2026 data cutoff
- Dose optimization arm designed to inform dose/regimen selection for planned Phase 3 registrational trial in desmoid tumors
- Zolucatetide has FDA Fast Track Designation and Orphan Drug Designation for desmoid tumors
- Investor webcast scheduled for October 24, 2026 at 12:00 p.m. EDT to discuss the data
- Estimated 30,000 people in the U.S. living with desmoid tumors, ~11,000 actively managed
Financial Impact
No financial data disclosed; clinical-stage company with no approved products or revenue
Risk Factors
- Phase 1/2 data may not support the planned dose/regimen for Phase 3, causing trial delays or redesign
- Efficacy or safety signals from the updated data cutoff could disappoint vs expectations
- Clinical-stage biotech with no approved products — high binary risk around pipeline milestones
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383275 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 2d ago | Press Release | $24.79 | awaiting T+60 | — | $25.03 (+0.97%) |
Oct 19, 2026 7d ago | Press Release | $25.35 | awaiting T+60 | — | $25.03 (−1.26%) |
Sep 15, 2026 5w ago | 8-K | $36.88 | awaiting T+60 | — | $25.03 (−32.13%) |
Sep 2, 2026 7w ago | 8-K | $40.75 | awaiting T+60 | — | $25.03 (−38.58%) |
Aug 13, 2026 10w ago | 8-K | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Aug 13, 2026 10w ago | Press Release | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Jul 22, 2026 13w ago | Insider Buy | $32.81 $22.75 | ▼ −30.66% | ▼ −34.31% | $25.03 (−23.71%) |
Jun 29, 2026 17w ago | Insider Cluster | $29.19 $33.31 | ▲ +14.11% | ▲ +10.50% | $25.03 (−14.25%) |
Jun 16, 2026 18w ago | Insider Cluster | $26.03 $36.16 | ▲ +38.92% | ▲ +36.23% | $25.03 (−3.84%) |
Jun 15, 2026 18w ago | Insider Cluster | $26.59 $36.88 | ▲ +38.70% | ▲ +36.84% | $25.03 (−5.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers